liabilities totaled $
30
million at March 31, 2025. In addition, Abbott recognized asset impairment charges of $
12
million related to these restructuring plans.
In 2024 and 2023, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices, diagnostic, nutritional and established pharmaceutical businesses, including the discontinuation of its ZonePerfect
®
product line in 2024.
In addition, Abbott recognized asset impairment charges of approximately $
30
million related to these restructuring plans in the first three months of 2024.
The following summarizes the activity related to these restructuring actions and the status of the related accruals as of March 31, 2025:
12
Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 8 — Incentive Stock Programs
In the first three months of 2025, Abbott granted
1,426,812
stock options,
354,001
restricted stock awards and
4,240,698
restricted stock units under its incentive stock program. At March 31, 2025,
50
million shares were reserved for future grants.
Information regarding the number of options outstanding and exercisable at March 31, 2025 is as follows:
The total unrecognized share-based compensation cost at March 31, 2025 amounted to $
790
million, which is expected to be recognized over the next
three years
.
Note 9 — Debt and Lines of Credit
On March 17, 2025, Abbott repaid the $
1.0
billion outstanding principal amount of its
2.95
% Notes upon maturity.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $
7.0
billion at March 31, 2025 and  December 31, 2024, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2025 will be included in Cost of products sold at the time the products are sold, generally through the next
twelve
to
eighteen months
.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and